Investor Type | Firm |
Type of Fund | Venture Capital Fund |
Industries | BioTech • HealthTech (& Fitness) • Medical Devices (& Hospital Services) • Healthcare (& Wellness) • Consumer • Pharmaceutical (& Medicine) |
Stages | Seed, Startup, Early Stage, Series A |
Investing | Germany • Netherlands • Brazil • Belgium |
Investment Range | $100,000 - $1,000,000 |
Investment Sweet Spot | $500,000 |
Assets Under Management | $250,000,000 |
BioGeneration Ventures (BGV) is a venture capital fund with a primary focus on early-stage investments in the life sciences sector. BGV operates with a clear investment thesis centered on nurturing breakthroughs in biotechnology, health technology, medical devices, healthcare services, consumer health, and pharmaceuticals. With an expertise in equity investments, BGV strategically allocates funds to transformative companies, targeting a minimum investment of 100,000 euros and a maximum of 1,000,000 euros. Their investment 'sweet spot' typically lies around 500,000 euros. Aimed at fueling innovation from the seed stage through to Series A rounds, BGV prioritizes startups with the potential to address unmet medical needs and improve patient outcomes. The firm takes a hands-on approach to support their portfolio companies, leveraging their industry expertise, broad network, and resources to accelerate growth and development. With assets under management totaling 250 million euros, BGV is positioned to make a significant impact in the healthcare and life sciences ecosystems, fostering the advancement of novel and promising therapeutics, medical technologies, and services that aim to revolutionize healthcare practices. Headquartered in Naarden, the Netherlands, BGV's strategic geographic presence affords them a strong foundation to tap into the burgeoning European life sciences sector, furthering their commitment to fostering innovation and enabling the next generation of healthcare solutions.